The next step from high-flux dialysis: Application of sorbent technology

Blood Purification

Volumn 20, Issue 1, 2002, Pages 81-86

  Winchester, James F ^a   Ronco, Claudio ^b   Brady, James A ^a   Cowgill, Larry D ^c   Salsberg, Jamie ^a   Yousha, Eric ^a   Choquette, Mike ^a   Albright, Robert ^a   Clemmer, Jonathan ^a   Davankov, Vadim ^d   Tsyurupa, Maria ^d   Pavlova, Ludmila ^d   Pavlov, Mikhail ^d   Cohen, Gerald ^e   Hörl, Walter ^e   Gotch, Frank ^f   Levin, Nathan W ^g  

^a RenalTech International   (United States)

^b SAN BORTOLO HOSPITAL   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^e UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g RENAL RESEARCH INSTITUTE   (United States)

Author keywords

2 Microglobulin; Adsorption; Angiogenin; Biocompatibility; Cytokines; Hemoperfusion; Leptin; Sorbents

Indexed keywords

ANGIOGENIN; BETA 2 MICROGLOBULIN; CHARCOAL; CYTOKINE; LEPTIN; RESIN; SORBENT;

ADSORPTION; ARTICLE; BIOCOMPATIBILITY; COST; DEVICE; DIALYSIS; HEMOPERFUSION; HUMAN; LEUKOCYTE; MOLECULAR WEIGHT; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SAFETY; TECHNOLOGY; THROMBOCYTE; ANIMAL; BLOOD; INSTRUMENTATION; METHODOLOGY; RENAL REPLACEMENT THERAPY; REVIEW; STANDARD;

ADSORPTION; ANIMAL; BETA 2-MICROGLOBULIN; HEMOPERFUSION; HUMAN; RENAL REPLACEMENT THERAPY; RESINS, SYNTHETIC; ANIMALS; HUMANS;

EID: 0036007329     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046989     Document Type: Article

References (42)

1. Effect of the hemodialysis prescription on patient morbidity: Report from the National Cooperative Dialysis Study
2. Excerpts from the United States Renal Data System 1998 Annual Data Report. Patient Mortality and Survival
3. Design and statistical issues of the hemodialysis (HEMO) study
4. Effects of hemodialyzer reuse on clearances of urea and β2-microglobulin
5. Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study
6. Oral enteral supplement use during baseline in the HEMO trial
7. The removal of uremic toxins
8. Clinical significance of granulocyte-inhibiting proteins
9. Hemodiafiltration with online regeneration of the ultrafiltrate
10. A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study
11. Fitness of biocompatible high-flux hemodiafiltration for dialysis-related amyloidosis
12. Plasma exchange and hemoperfusion
13. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove β2-microglobulin in hemodialysis
14. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients
15. The measurement of cytokine production capacity during dialysis - A new dynamic method for the evaluation of biocompatibility?
16. Oxidative protein damage with carbohydrates and lipids in uremia: Carbonyl stress
17. Assessment of inflammation and nutrition in patients with end-stage renal disease
18. Biological markers in the diagnosis of the different forms of renal osteodystrophy
19. A new form of amyloid protein associated with hemodialysis was identified as β2-microglobulin
20. β2-Microglobulin modified with AGE products of the Maillard reaction in dialysis-related amyloidosis
21. 125I-β2-microglobulin turnover in dialyzed patients
22. β2-Microglobulin and amyloidosis
23. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients
24. Effect of dialyzer reprocessing with Renalin on serum β2-microglobulin and complement activation in hemodialysis patients
25. Effect of dialyzer reuse: Dissociation between clearances of small and large solutes
26. Clinical, radiological and serum amyloid P component scintigraphic features of β2-microglobulin amyloidosis associated with continuous ambulatory peritoneal dialysis
27. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura
28. Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): Clinical experience from a single center
29. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure
30. Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasma perfusion
31. Experimental study of extracorporeal perfusion for septic shock
32. Extracorporeal techniques in the treatment of poisoned patients
33. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove β2-microglobulin in hemodialysis
34. Solute, amino acid and hormone changes with coated charcoal hemoperfusion in uremia
35. Ex-vivo biocompatibility of a new β2-microglobulin adsorbent during hemoperfusion with human whole blood
36. Effects of a new adsorbent column for removing β2-microglobulin from circulating blood of dialysis patients
37. The clinical study on the newer type (Lixelle type S-15) of the direct hemoperfusion B2-MG adsorption column
38. Clinical performance of a new high-flux synthetic membrane
39. In vitro and in vivo evaluation of a new polysulfone membrane for hemodialysis. Reference methodology and clinical results. (Part 2. In vivo study)
40. On-line haemodiafiltration. Remarkable removal of β2-microglobulin. Longterm clinical results
41. Ex vivo cytokine clearance with a new adsorbent material from endotoxin-stimulated whole blood